104 related articles for article (PubMed ID: 12399127)
1. Intrapleural interleukin-2 induces nitric oxide production in pleural effusions from malignant mesothelioma: a possible mechanism of interleukin-2-mediated cytotoxicity?
Porta C; Rizzo V; Zimatore M; Sartore-Bianchi A; Danova M; Mutti L
Lung Cancer; 2002 Nov; 38(2):159-62. PubMed ID: 12399127
[TBL] [Abstract][Full Text] [Related]
2. Palliative and therapeutic activity of IL-2 immunotherapy in unresectable malignant pleural mesothelioma with pleural effusion: Results of a phase II study on 31 consecutive patients.
Castagneto B; Zai S; Mutti L; Lazzaro A; Ridolfi R; Piccolini E; Ardizzoni A; Fumagalli L; Valsuani G; Botta M
Lung Cancer; 2001; 31(2-3):303-10. PubMed ID: 11165411
[TBL] [Abstract][Full Text] [Related]
3. Intrapleural administration of interleukin 2 in pleural mesothelioma: a phase I-II study.
Goey SH; Eggermont AM; Punt CJ; Slingerland R; Gratama JW; Oosterom R; Oskam R; Bolhuis RL; Stoter G
Br J Cancer; 1995 Nov; 72(5):1283-8. PubMed ID: 7577483
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of intrapleural cisplatin for the treatment of malignant pleural effusions.
Monjanel-Mouterde S; Frenay C; Catalin J; Boutin C; Durand A; Astoul P
Oncol Rep; 2000; 7(1):171-5. PubMed ID: 10601613
[TBL] [Abstract][Full Text] [Related]
5. IL-6 in malignant pleural effusions and its augmentation by intrapleural instillation of IL-2.
Yanagawa H; Sone S; Munekata M; Atagi S; Nii A; Ogura T
Clin Exp Immunol; 1992 May; 88(2):207-12. PubMed ID: 1315227
[TBL] [Abstract][Full Text] [Related]
6. Intrapleural administration of interleukin-2 for the treatment of patients with malignant pleural mesothelioma: a Phase II study.
Astoul P; Picat-Joossen D; Viallat JR; Boutin C
Cancer; 1998 Nov; 83(10):2099-104. PubMed ID: 9827714
[TBL] [Abstract][Full Text] [Related]
7. Phase I clinical and pharmacological study of liposome-entrapped NDDP administered intrapleurally in patients with malignant pleural effusions.
Perez-Soler R; Shin DM; Siddik ZH; Murphy WK; Huber M; Lee SJ; Khokhar AR; Hong WK
Clin Cancer Res; 1997 Mar; 3(3):373-9. PubMed ID: 9815694
[TBL] [Abstract][Full Text] [Related]
8. [Intrapleural administration of recombinant interleukin-2 in a patient with pleural effusion due to non-Hodgkin's lymphoma].
Kojiro N; Ishihara H; Ito M; Nishiki M; Yamashita K; Onoshi M
Nihon Kyobu Shikkan Gakkai Zasshi; 1989 Aug; 27(8):954-9. PubMed ID: 2615111
[TBL] [Abstract][Full Text] [Related]
9. Induction of lymphokine-activated killer cells by intrapleural instillations of recombinant interleukin-2 in patients with malignant pleurisy due to lung cancer.
Yasumoto K; Mivazaki K; Nagashima A; Ishida T; Kuda T; Yano T; Sugimachi K; Nomoto K
Cancer Res; 1987 Apr; 47(8):2184-7. PubMed ID: 3493843
[TBL] [Abstract][Full Text] [Related]
10. Intrapleural administration of interleukin-2 for the treatment of patients with malignant pleural mesothelioma: a Phase II study.
Karrison TG; Vogelzang NJ
Cancer; 1999 Aug; 86(3):546-7. PubMed ID: 10430267
[No Abstract] [Full Text] [Related]
11. A phase I clinical trial of single-dose intrapleural IFN-beta gene transfer for malignant pleural mesothelioma and metastatic pleural effusions: high rate of antitumor immune responses.
Sterman DH; Recio A; Carroll RG; Gillespie CT; Haas A; Vachani A; Kapoor V; Sun J; Hodinka R; Brown JL; Corbley MJ; Parr M; Ho M; Pastan I; Machuzak M; Benedict W; Zhang XQ; Lord EM; Litzky LA; Heitjan DF; June CH; Kaiser LR; Vonderheide RH; Albelda SM; Kanther M
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4456-66. PubMed ID: 17671130
[TBL] [Abstract][Full Text] [Related]
12. [Experimental and clinical studies on intrapleural instillations of interleukin-2 (IL-2) in patients with malignant pleural effusion].
Suzuki H
Nihon Geka Gakkai Zasshi; 1989 Nov; 90(11):1922-31. PubMed ID: 2608022
[TBL] [Abstract][Full Text] [Related]
13. Intrapleural cisplatin and mitomycin for malignant mesothelioma following pleurectomy: pharmacokinetic studies.
Rusch VW; Niedzwiecki D; Tao Y; Menendez-Botet C; Dnistrian A; Kelsen D; Saltz L; Markman M
J Clin Oncol; 1992 Jun; 10(6):1001-6. PubMed ID: 1588364
[TBL] [Abstract][Full Text] [Related]
14. Tumour necrosis factor-alpha and nitric oxide, determined as nitrite, in malignant pleural effusion.
Agrenius V; Gustafsson LE; Widström O
Respir Med; 1994 Nov; 88(10):743-8. PubMed ID: 7846335
[TBL] [Abstract][Full Text] [Related]
15. Intrapleural production of interleukin 6 during mesothelioma and its modulation by gamma-interferon treatment.
Monti G; Jaurand MC; Monnet I; Chretien P; Saint-Etienne L; Zeng L; Portier A; Devillier P; Galanaud P; Bignon J
Cancer Res; 1994 Aug; 54(16):4419-23. PubMed ID: 8044791
[TBL] [Abstract][Full Text] [Related]
16. Interleukin 6 and its relationship to clinical parameters in patients with malignant pleural mesothelioma.
Nakano T; Chahinian AP; Shinjo M; Tonomura A; Miyake M; Togawa N; Ninomiya K; Higashino K
Br J Cancer; 1998 Mar; 77(6):907-12. PubMed ID: 9528833
[TBL] [Abstract][Full Text] [Related]
17. Intrapleural tetracycline in malignant pleural effusions. A randomized study.
Zaloznik AJ; Oswald SG; Langin M
Cancer; 1983 Feb; 51(4):752-5. PubMed ID: 6336983
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of intrapleural recombinant interleukin-2 in immunotherapy for malignant pleural effusion.
Astoul P; Bertault-Peres P; Durand A; Catalin J; Vignal F; Boutin C
Cancer; 1994 Jan; 73(2):308-13. PubMed ID: 8293393
[TBL] [Abstract][Full Text] [Related]
19. Intrapleural cisplatin and cytarabine in the management of malignant pleural effusions: a Lung Cancer Study Group trial.
Rusch VW; Figlin R; Godwin D; Piantadosi S
J Clin Oncol; 1991 Feb; 9(2):313-9. PubMed ID: 1988578
[TBL] [Abstract][Full Text] [Related]
20. Eosinophil colony-stimulating factor induced by administration of interleukin-2 into the pleural cavity of patients with malignant pleurisy.
Nakamura Y; Ozaki T; Yanagawa H; Yasuoka S; Ogura T
Am J Respir Cell Mol Biol; 1990 Oct; 3(4):291-300. PubMed ID: 2206537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
